Invesco China Health Care Equity Fd.Z H
LU2305833662
Invesco China Health Care Equity Fd.Z H/ LU2305833662 /
NAV2024-09-20 |
Chg.-0.0600 |
Type of yield |
Investment Focus |
Investment company |
3.7400EUR |
-1.58% |
paying dividend |
Equity
Sector Health / Pharma
|
Invesco Management ▶ |
Investment strategy
The objective of the Fund is to achieve long term capital growth. The Fund invests in Chinese healthcare companies listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect as well as those listed or traded elsewhere, included Qualified Foreign Investors (QFI). The Fund invests in companies which are attractively valued and demonstrate sustainable growth, along with a strong business model and sound balance sheet. For the purposes of the Fund, healthcare companies include (but are not limited to) companies in the sectors of pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.
The Fund may use derivatives (complex instruments) to manage the Fund more efficiently, with the aim of reducing risk, reducing costs and/or generating additional capital or income. The Fund is actively managed and is not constrained by its benchmark, MSCI China A Onshore Health Care Index, which is used for comparison purposes. However, as the benchmark is a suitable proxy for the investment strategy, it is likely that some of the Fund"s holdings are also components of the benchmark. As an actively managed fund, this overlap will change and this statement may be updated from time to time.
Investment goal
The objective of the Fund is to achieve long term capital growth. The Fund invests in Chinese healthcare companies listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect as well as those listed or traded elsewhere, included Qualified Foreign Investors (QFI). The Fund invests in companies which are attractively valued and demonstrate sustainable growth, along with a strong business model and sound balance sheet. For the purposes of the Fund, healthcare companies include (but are not limited to) companies in the sectors of pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.
Master data
Type of yield: |
paying dividend |
Funds Category: |
Equity |
Country: |
China |
Branch: |
Sector Health / Pharma |
Benchmark: |
MSCI China A Onshore Health Care Index |
Business year start: |
02-29 |
Last Distribution: |
- |
Depository bank: |
- |
Fund domicile: |
Luxembourg |
Distribution permission: |
Austria, Germany, Switzerland, Luxembourg, Czech Republic |
Fund manager: |
Chris Liu, Kehong Jiang |
Fund volume: |
349.2 mill.
EUR
|
Launch date: |
2021-03-03 |
Investment focus: |
- |
Conditions
Issue surcharge: |
5.00% |
Max. Administration Fee: |
0.75% |
Minimum investment: |
1,000.00 EUR |
Deposit fees: |
0.01% |
Redemption charge: |
0.00% |
Key Investor Information: |
Download (Print version) |
Investment company
Funds company: |
Invesco Management |
Address: |
An der Welle 5, 60322, Frankfurt am Main |
Country: |
Germany |
Internet: |
www.de.invesco.com
|
Countries
China |
|
94.70% |
Cash |
|
3.10% |
Hong Kong, SAR of China |
|
2.20% |
Branches
Pharma, production |
|
45.70% |
Healthcare |
|
38.10% |
Pharma/Biotechnology |
|
13.00% |
Cash |
|
3.10% |
Others |
|
0.10% |